What podcasts say about Amgen
Every statement, with the speaker, the exact quote and the moment it was said.
What experts have said about Amgen
22 statements · 16 positive · 4 negative · 1 mixed · 1 neutral
Amgen’s phase three Sjögren’s trial produced very strong results.
“Amgen sort of hit it out of the ballpark in the phase three”
Open the episode · Episode 202 - November 6, 2026Listen at 55:00
Amgen will probably file its obesity pen application in the second half of next year if successful.
“they're probably going to be filing assuming success in the second half of next year with the pen.”
Open the episode · Episode 202 - November 6, 2026Listen at 55:58
Amgen is a value investment yielding approximately 6%.
“this is a value play that pays you 6%”
Open the episode · Cracks In The AI Trade… And AMD Reports Results 11/3/26Listen at 20:12
Amgen’s replacement drugs are already offsetting patent-expiration revenue losses.
“Amgen is over the patent cliff already. It's replacement drugs. are already replacing that revenue.”
Open the episode · Cracks In The AI Trade… And AMD Reports Results 11/3/26Listen at 21:28
Amgen could become an attractive pullback buy depending on tomorrow’s action.
“it could end up being a great pullback buy here depending on what the pullback looks like tomorrow.”
Open the episode · AI, Chip Stocks Lead Nasdaq Rebound: AMD, Methanex, Hilton In FocusListen at 27:03
Amgen enrolled its Lp(a) study in 16 months, faster than Novartis.
“they are leap and bounce faster than anybody else recall they enrolled their lp little a study in 16 months”
Open the episode · Episode 201 - October 30, 2026Listen at 20:39
Amgen’s Delphi 305 data appeared practice-changing in small-cell lung cancer.
“I did see at least that as a practice-changing data set.”
Open the episode · Episode 201 - October 30, 2026Listen at 43:21
Delphi 305 is likely to change small-cell lung-cancer standard of care.
“this is standard of care changing.”
Open the episode · Episode 201 - October 30, 2026Listen at 49:45
Delphi 312 is expected to succeed after Delphi 305.
“I'm pretty convinced will be successful too”
Open the episode · Episode 201 - October 30, 2026Listen at 50:01
Amgen is clearly under institutional accumulation.
“a stock that's clearly... under accumulation here”
Open the episode · Tech Stocks Hit, Yields Plunge As AI Trade Fizzles: NetApp, Amgen, Nasdaq In FocusListen at 12:20
Amgen presents an actionable buy setup.
“a stock that's actionable here”
Open the episode · Tech Stocks Hit, Yields Plunge As AI Trade Fizzles: NetApp, Amgen, Nasdaq In FocusListen at 12:35
Amgen is a solid blue-chip with a strong technical setup.
“Amgen is just a really solid blue-chip name and great technical setup here”
Open the episode · Tech Stocks Hit, Yields Plunge As AI Trade Fizzles: NetApp, Amgen, Nasdaq In FocusListen at 12:51
Amgen tends to trade orderly, with ATR around 2.5%.
“the ATR is down around the 2.5%, so it tends to trade fairly orderly”
Open the episode · Tech Stocks Hit, Yields Plunge As AI Trade Fizzles: NetApp, Amgen, Nasdaq In FocusListen at 13:40
Amgen is developing a treatment similar to Novartis's cardiovascular drug.
“Amgen is working on a similar treatment.”
Open the episode · Apple Event, Treasury Auction Fill Time Before PPIListen at 5:27
Novartis’s news is dragging down Amgen shares.
“shares of Amgen, for instance, which is also in late-stage testing of its own heart disease drug, also being dragged down as a result of this news from Novartis.”
Open the episode · Novartis Drop; Boston Scientific Cyberattack; Intel RisesListen at 1:26
Novartis’s news is dragging down Amgen shares.
“Shares of Amgen, for instance, which is in late-stage testing of its own heart disease medication, also being dragged down by this news from Novartis.”
Open the episode · Novartis and Boston Scientific Slide; Intel Price HikesListen at 1:31
Amgen’s cardiovascular drug will likely produce a Novartis-like trial readout.
“it's likely that Amgen's drug is probably going to give a similar readout”
Open the episode · AI Stocks Lead, Blue Chips Lag In Down Session: AMD, Magnite, TVTX In FocusListen at 6:05
Amgen could drop its cardiovascular drug without much further stock decline.
“Amgen could remove that drug from its portfolio, and the stock probably wouldn't go down all that much more.”
Open the episode · 'Mad Money w/ Jim Cramer 9/8/26Listen at 7:00
Amgen stock could rise on earnings and weight-loss-drug news
“That plus good earnings and maybe some good news about this weight loss drug could send this Dow stock higher.”
Open the episode · Mad Money w/ Jim Cramer 1/30/26Listen at 4:39
Amgen’s pipeline, earnings, and weight-loss news could lift its stock.
“could send this Dow stock higher”
Open the episode · Mad Money w/ Jim Cramer 1/30/26Listen at 4:42
Amgen is another stock Cramer favors alongside Regeneron.
“I'll give you two for so is Amgen.”
Open the episode · Mad Money w/ Jim Cramer 11/20/25Listen at 31:19
Amgen needs to broaden its portfolio through strategic action.
“I think Amgen needs to do something because they've got to broaden the portfolio”
Open the episode · Mad Money w/ Jim Cramer 11/5/25Listen at 9:21
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.